

Prostate MRI: When do we really need it?

Poster Session 40

Sunday, 13 March
14:00 - 15:30

Location: Room Madrid (Hall B2, level 0)

Chairs: C.L. Dickinson, London (GB)
M. Emberton, London (GB)
B.A. Hadaschik, Heidelberg (DE)

Aims and objectives of this presentation

Prostate MRI is gaining more importance in diagnosis of prostate cancer but the exact indication is still unclear. This session will highlight new data on the indication for an MRI before the first and second biopsy and in active surveillance patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*497

Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam

By: [Alberts A.](#)¹, [Roobol M.](#)¹, [Bokhorst L.](#)¹, [Drost F-J.](#)², [Van Leenders G.](#)³, [Dwarkasing R.](#)², [Barentsz J.](#)⁴, [Schröder F.](#)¹, [Bangma C.](#)¹, [Schoots I.](#)²

Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Radboudumc, Dept. of Radiology, Nijmegen, The Netherlands

*498

The UCL PICTURE trial: A prospective cohort validating study evaluating the accuracy of multi-parametric MRI and prostate HistoScanning compared to transperineal template mapping biopsies in patients requiring risk stratification after prior transrectal prostate biopsy

By: [Simmons L.](#)¹, [Kanthabalan A.](#)¹, [Hu Y.](#)², [Barrat D.](#)², [Punwani S.](#)³, [Ramachandran N.](#)³, [Jameson C.](#)⁴, [Freeman A.](#)⁴, [McCartan N.](#)¹, [Briggs T.](#)⁵, [Gelister J.](#)⁵, [Charman S.](#)⁶, [Van Der Muelen J.](#)⁶, [Moore C.](#)¹, [Ahmed H.](#)¹, [Emberton M.](#)¹

Institutes:¹University College Hospitals London, Dept. of Surgery and Interventional Science, London, United Kingdom, ²University College London, Centre For Medical Imaging and Computing, London, United Kingdom, ³University College Hospitals London, Dept. of Radiology, London, United Kingdom, ⁴University College Hospital London, Dept. of Pathology, London, United Kingdom, ⁵Barnet Hospital, The Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁶London School of Hygiene and Tropical Medicine, Dept. of Health Services Research and Policy, London, United Kingdom

*499

A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Preliminary results

By: [Porpiglia F.](#)¹, [Mele F.](#)¹, [Manfredi M.](#)¹, [Aimar R.](#)¹, [Checcucci E.](#)¹, [Cossu M.](#)¹, [Bollito E.](#)², [Russo F.](#)³, [Gned D.](#)⁴, [De Pascale A.](#)⁴, [Cirillo S.](#)⁵, [Fiori C.](#)¹

Institutes:¹San Luigi Gonzaga Hospital, Dept. of Urology, University of Turin, Orbassano, Turin, Italy, ²San Luigi Gonzaga Hospital, Dept. of Pathology, University of Turin, Orbassano, Turin, Italy, ³Candiolo Cancer Institute, Division of Radiology, Candiolo, Turin, Italy, ⁴San Luigi Gonzaga Hospital, Division of Radiology, University of Turin, Orbassano, Turin, Italy, ⁵Mauriziano Hospital, Division of Radiology, Turin, Italy

*500

Multiparametric magnetic resonance imaging and MRI/TRUS-fusion-biopsy for index tumor detection: Correlation with radical prostatectomy specimen

By: [Radtke J.P.](#)¹, [Schwab C.](#)¹, [Wolf M.](#)², [Freitag M.](#)², [Alt C.](#)³, [Kesch C.](#)¹, [Popeneciu I.V.](#)¹, [Huettnerbrink](#)

C.¹, Gasch C.¹, Klein T.¹, Duensing S.⁴, Roth W.⁵, Schueler S.⁶, Stock C.⁶, Schlemmer H-P.², Roethke M.C.², Hohenfellner M.¹, Hadaschik B.¹

Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, ³Heinrich-Heine University Düsseldorf, Dept. of Radiology, Düsseldorf, Germany, ⁴University Hospital Heidelberg, Dept. of Urology, Section of Molecular Urooncology, Heidelberg, Germany, ⁵University of Heidelberg, Dept. of Pathology, Heidelberg, Germany, ⁶University of Heidelberg, Dept. of Medical Biometry and Informatics, Heidelberg, Germany

*501

Is a negative mpMRI really able to rule out significant prostate cancer?

By: Branger N.¹, Maubon T.¹, Traumann M.¹, Thomassin J.², Pacienza M.², Brunelle S.³, Salem N.⁴, Gravis G.⁵, Walz J.¹

Institutes:¹Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ²Institut Paoli-Calmettes, Dept. of Pathology, Marseille, France, ³Institut Paoli-Calmettes, Dept. of Radiology, Marseille, France, ⁴Institut Paoli-Calmettes, Dept. of Radiotherapy, Marseille, France, ⁵Institut Paoli-Calmettes, Dept. of Oncology, Marseille, France

*502

Multiparametric MRI and MRI-TRUS fusion-biopsy in patients with prior negative prostate biopsy

By: Kesch C.¹, Radtke J.P.¹, Roth W.², Roethke M.³, Schlemmer H.P.³, Hohenfellner M.¹, Hadaschik B.¹

Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany, ³German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany

*503

Evaluation of PI-RADS classification in prediction of tumor-aggressiveness in targeted biopsy

By: Borkowetz A.¹, Platzek I.², Toma M.³, Renner T.¹, Fröhner M.¹, Koch R.⁴, Zastrow S.¹, Wirth M.¹

Institutes:¹University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, ²University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, ³University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany, ⁴University Hospital, TU Dresden, Institute For Medical Informatics and Biometry, Dresden, Germany

*504

Poor reproducibility of PI-RADS score in 2 multiparametric MRIs before biopsy in men with elevated PSA

By: Müller S., Løfsgaard L., Estop-Garanto M., Sand T.E., Helgø D., Sund P., Mygland V.

Institutes:Akershus University Hospital, Dept. of Urology, Lørenskog, Norway

*505

Targeted PET/TRUS software fusion-guided biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy: A feasibility study and preliminary results

By: Lopci E.², Lazzeri M.¹, Lughezzani G.¹, Pasini L.¹, Hurle R.¹, Leonardi L.², Casale P.¹, Buffi N.¹, Peschechera R.¹, Rodari M.², Zandegiacomo S.¹, Benetti A.¹, Fiorini G.¹, Chiti A.³, Guazzoni G.⁴

Institutes:¹Istituto Clinico Humanitas IRCCS, Dept. of Urology, Milan, Italy, ²Istituto Clinico Humanitas IRCCS, Dept. of Nuclear Medicine, Milan, Italy, ³Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Nuclear Medicine, Milan, Italy, ⁴Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Urology, Milan, Italy

*506

MRI guided prostate biopsy: What is the place of PCA3 score?

By: Roumiguie M.¹, Beauval J.B.¹, Nogueira L.², Portalez D.³, Soulie M.¹, Rischmann P.¹, Malavaud B.¹

Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²CHU Purpan, Dept. of Biology, Toulouse, France, ³CHU Rangueil, Dept. of Radiology, Toulouse, France

*507

Low apparent diffusion coefficient (ADC) value is associated with biochemical recurrence in high risk prostate cancer patients

By: Park J., Yoon M.Y., Kim J.K., Kim H.S., Jeong C.W., Ku J.H., Kim H.H., Kwak C.

Institutes:Seoul National University Hospital, Dept. of Urology, Seoul, South Korea

15:13 - 15:20

Summary and context

B.A. Hadaschik, Heidelberg (DE)